The association of serum visfatin in women with polycystic ovary syndrome: A case-control study-Reference-Cited by-同舟云学术

The association of serum visfatin in women with polycystic ovary syndrome: A case-control study

Published:2022-12-15 Issue:4 Volume:7 Page:1-4
ISSN:1390-9347
Container-title:Bionatura
language:
Short-container-title:RB

Author:

Shamkhi Al- Ghazali Basima¹^ORCID,Ali Mohammed Ayyam²^ORCID,Muhi Fahad Ahmed³^ORCID

Affiliation:

1. Department of Gynecology and Obstetrics, College of Medicine, Kufa University, Al-Najaf, Iraq

2. Department of Gynecology and Obstetrics, Al-Najaf Health Directorate, Ministry of Health, Al-Najaf, Iraq;

3. Department of Cardiothoracic and Vascular Surgery, Al-Sadder Teaching Medical City, Al-Najaf Health Directorate, Ministry of Health, Al-Najaf, Iraq

Abstract

Polycystic ovarian syndrome (PCOS) is the most common endocrinopathy among women of reproductive age. Visfatin is an adipokine secreted by fat tissue and macrophages involved in regulating glucose homeostasis, adipose tissue inflammation, chronic systemic inflammation, cardiovascular disease and endothelial dysfunction. The study sample (100 patients) includes 50 PCOS women and 50 control matched for age and body mass index (BMI). The women with PCOS were divided into obese or overweighed according to BMI ≥ 25 Kg/m2 and non-obese BMI ≤ 25 Kg/m2. The control group was also divided into obese and non-obese. The results showed that serum visfatin was significantly increased in obese women with POCS compared to obese control (5.61 ± 1.27 ng/mL vs. 0.48 ±0.28 ng/mL) and in non-obese women with polycystic ovarian syndrome compared to non-obese control (5.22± 1.36 ng/mL vs. 0.33± 0.26 ng/mL). These findings might suggest that visfatin could play a role in pathogenesis and the long-term consequences of PCOS. Keywords: visfatin; polycystic ovarian syndrome; body mass index; obese women

Publisher

Clinical Biotec

Subject

Infectious Diseases,Applied Microbiology and Biotechnology,Epidemiology,Biotechnology

Reference22 articles.

1. 1. Sirmans, S. M., Pate, K. A. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical epidemiology, 2013, 6, 1–13. https://doi.org/10.2147/CLEP.S37559.

2. 2. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine, 2006, 30(1), 13–17. https://doi.org/10.1385/ENDO:30:1:13.

3. 3. Bargiota, A., & Diamanti-Kandarakis, E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Therapeutic advances in endocrinology and metabolism, 2012, 3(1), 27–47. https://doi.org/10.1177/2042018812437355.

4. 4. Fortuño, A., Rodríguez, A., Gómez-Ambrosi, J., Frühbeck, G., & Díez, J. Adipose tissue as an endocrine organ: role of leptin and adiponectin in the pathogenesis of cardiovascular diseases. Journal of physiology and biochemistry, 2003, 59(1), 51–60. https://doi.org/10.1007/BF03179868.

5. 5. Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Matsuki, Y., Murakami, M., Ichisaka, T., Murakami, H., Watanabe, E., Takagi, T., Akiyoshi, M., Ohtsubo, T., Kihara, S., Yamashita, S., Makishima, M., Funahashi, T., Yamanaka, S., Hiramatsu, R., … Shimomura, I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science (New York, N.Y.), 2005, 307(5708), 426–430. https://doi.org/10.1126/science.1097243.